	Inflammatory bowel disease
Crohnâ€™s disease
Immunotherapy
Quality of life
	certolizumab pegol 400 mg
certolizumab pegol
IBDQ total score
phase III studies
disease
IBDQ
analyses
HRQoL
patients
CDAI score
treatment
symptoms
moderate-to-severe active Crohn
week 10
clinical efficacy
study
efficacy
placebo group
effects
points
moderate-to-severe Crohn
Emotional Function domains
Crohn
placebo response rate
clinical benefit
placebo
CRP
Infliximab
mg group
baseline
life
improvements
domains
official
randomized
highest

